Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 15/08/2010

    Horizon Pharma - Nitec Pharma and Horizon Therapeutics combine businesses

    Nitec Pharma AG, a spin-off from Merck (Darmstadt, Germany) and Horizon Therapeutics, Inc. (USA) have announced the combination of their businesses to become Horizon Pharma, Inc. and the filing of a registration statement for a proposed initial public offering. The company’s Mannheim-based subsidiary, which is focused on the development and commercialisation of drugs for the treatment of pain and chronic inflammatory diseases, has been named…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/horizon-pharma-nitec-pharma-and-horizon-therapeutics-combine-businesses
  • Press release - 30/03/2009

    Vetter to secure growth with new subsidiary

    Vetter Pharma-Fertigung GmbH Co. KG have announced the establishment of a new subsidiairy Vetter Pharma International GmbH VPI. The launch is scheduled for April 1st 2009. Peter Sölkner will be the Managing Director and is one of three Vetter managers appointed since June 2008.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-to-secure-growth-with-new-subsidiary
  • Article - 16/04/2012 16946_de.jpg

    Pharma 2.0: towards paperless production

    Before electronic solutions existed lorries were needed to ship new drug applications which often comprised 500000 or so pages. Thanks to IT this is no longer necessary. IT-based procedures and solutions are playing an increasing role in all areas of the pharmaceutical industry. Markus Roemer CEO of Ravensburg-based comes compliance services supports companies in implementing legal guidelines in this area. In the following interview Roemer talks…

    https://www.gesundheitsindustrie-bw.de/en/article/news/pharma-2-0-towards-paperless-production
  • Press release - 19/10/2009

    New ulcerative colitis therapy in sight

    Lipid Therapeutics GmbH and Dr. Falk Pharma GmbH announced on 30th, September, that they have entered into a co-development and licensing agreement for LT-02. Under the terms of the agreement, Dr. Falk Pharma will receive exclusive access to the European rights to Lipid Therapeutics’ lead product LT-02 for the treatment of ulcerative colitis. Ulcerative colitis is a severe inflammation of the colon affecting more than one million people…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ulcerative-colitis-therapy-in-sight
  • Press release - 08/04/2010 Logo of Boehringer Ingelheim

    Latest Trend: Investment-Fonds by Big Pharma

    Boehringer Ingelheim announced the launch of its corporate venture capital fund the Boehringer Ingelheim Venture Fund BIVF. The BIVF aims to invest in Biotech and Start-up companies that provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical science.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/latest-trend-investment-fonds-by-big-pharma
  • Press release - 26/03/2009 08265_de.jpg

    Sygnis Pharma AG increases capital

    SYGNIS Pharma AG reported its financial results for the first nine months of the fiscal year 20082009. The company improved its cash position significantly as a result of a successful capital increase. Following the capital increase the stake of dievini Hopp BioTech in SYGNIS Pharma AG increased to approximately 44.90 of the total share capital. The preparations for the phase II efficacy trial of its lead candidate AX200 in acute ischemic stroke…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-pharma-ag-increases-capital
  • Article - 24/10/2011 15618_de.jpg

    Ascendis Pharma: transient drug conjugates

    Ascendis Pharma’s proprietary technology platform, TransCon, is a novel prodrug technology for the production of new patentable versions of drugs already on the market, which has been developed for improving the dosage form and effect in patients. A Phase II clinical study of Ascendis Pharma’s most advanced drug candidate, a PEGylated growth hormone that only needs to be administered once-weekly to growth hormone-deficient adults, has recently…

    https://www.gesundheitsindustrie-bw.de/en/article/news/ascendis-pharma-transient-drug-conjugates
  • Press release - 04/11/2010

    SYGNIS Pharma AG announces restructuring

    SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today a comprehensive, strategic restructuring of the company, which will include significant personnel and cost reductions. The process has been approved by the Supervisory Board and will be executed immediately.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-pharma-ag-announces-restructuring
  • Press release - 09/02/2008

    Pharma and life sciences industry as growth sector

    The CEOs of pharmaceutical and life science companies are becoming increasingly aware that their companies are facing growing challenges and risks at the global level. At the same time they are also aware of more and more opportunities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pharma-and-life-sciences-industry-as-growth-sector
  • Press release - 22/10/2009 SYGNIS Pharma AG Logo

    SYGNIS secures up to € 10 Million through a 3 year Standby Equity Distribution Agreement (SEDA) with Yorkville

    SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard), a clinical stage biotech company developing innovative CNS treatments, today announced that it has entered into a 3 year standby equity distribution agreement (SEDA) with YA Global Master SPV LTD (YA Global) a fund managed by Yorkville Advisors, LLC located in New Jersey USA.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-secures-up-to-10-million-through-a-3-year-standby-equity-distribution-agreement-seda-with-yor
  • Press release - 13/10/2009 Trenzyme Logo

    Trenzyme receives ISO 9001 certification

    The Trenzyme GmbH has set another milestone as a first class service provider for the pharma and life science industry.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/trenzyme-receives-iso-9001-certification
  • Press release - 11/06/2010 Photo of Markus Roemer, managing director of ‘comes compliance services‘

    comes compliance services enriches BioLAGO network

    The addition of comes compliance services to the BioLAGO network broadens the life sciences associations skills in the fields of regulatory requirements and quality management systems. The company offers quality management systems audit services IT project management services quality risk management and validation services.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/comes-compliance-services-enriches-biolago-network
  • Article - 09/07/2012 The photo shows a number of Vetter Pharma's apprentices, bachelor’s, master’s and diploma graduates. Continuous growth has meant that Vetter Pharma has had to recruit increasing numbers of new staff.

    Bachelor’s and master’s graduates – what really counts is individual aptitude

    Ravensburg-based Vetter Pharma GmbH has been constantly growing over the last few years; the company took on 300 new staff in 2011 and plans to recruit 350 more in 2012. The company is desperately looking for qualified young people to help manage its growth. In what way does this impact on job opportunities for bachelor’s and master’s graduates? In the following interview, Christiane Priebe, Director of Human Resources at Vetter Pharma, talks…

    https://www.gesundheitsindustrie-bw.de/en/article/news/bachelor-s-and-master-s-graduates-what-really-counts-is-individual-aptitude
  • Press release - 16/11/2010 12926_de.jpg

    Nycomed is keeping the pace in third quarter 2010 - US Food & Drug Administration to decide on the approval of Daxas®

    Nycomed’s strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pantoprazole. Daxas® (roflumilast) has recently been launched in the first EU markets and further launches are underway over the coming months. To accelerate the expansion in China, one of the fastest…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-is-keeping-the-pace-in-third-quarter-2010-us-food-drug-administration-to-decide-on-the-appro
  • Article - 17/03/2008

    FDA approves Vetter Pharma client drug

    Vetter Pharma Fertigung GmbH Co has been granted approval by the American Food and Drug Administration FDA for the production of a new client drug. Vetter will now be filling injection systems with the new drug at its Ravensburg facility. Vetter has invested over 100 million euros.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/fda-approves-vetter-pharma-client-drug
  • Article - 04/02/2013 08265_de.jpg

    SYGNIS Pharma - the "new" one: development and commercialisation of molecular diagnostics products

    Heidelberg-based SYGNIS Pharma AG is to discontinue its therapeutic R&D projects targeting human nervous system diseases and will in future focus on the research and development of novel molecular biology technologies, including DNA amplification and sequencing as well as drug screening.

    https://www.gesundheitsindustrie-bw.de/en/article/news/sygnis-pharma-the-new-one-development-and-commercialisation-of-molecular-diagnostics-products
  • Press release - 10/10/2011 15536_de.jpg

    Vetter’s state-of-the-art Chicago facility is fully operational

    Vetter, a leading contract development and manufacturing organization that specializes in aseptic filling, today announced that its first U.S. facility is now fully operational. Located at the Illinois Science + Technology Park in suburban Chicago, the 24,000-square-foot site includes microbiology and chemical analysis labs, material preparation and compounding functions, three cleanrooms for aseptic filling, and visual inspection. The first to…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-s-state-of-the-art-chicago-facility-is-fully-operational
  • Article - 22/09/2008

    EMEA recommends Orphan Drug Designation for AX200

    SYGNIS Pharma AG announced that it has received a positive recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency for AX200 in the treatment of spinal cord injury.

    https://www.gesundheitsindustrie-bw.de/en/article/news/emea-recommends-orphan-drug-designation-for-ax200
  • Article - 23/08/2008

    Nycomed successfully closes oncology program

    Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomeds strategic decision not to further invest in oncology RD activities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-successfully-closes-oncology-program
  • The Baden-Württemberg healthcare industry

    The pharmaceutical industry

    Baden-Württemberg is Germany’s largest pharma location. In addition to industry giants such as Roche, GlaxoSmithKline and Boehringer Ingelheim, Baden-Württemberg is home to a large number of small- and medium-sized pharmaceutical companies and biotech companies with pharmaceutical research and development.

    https://www.gesundheitsindustrie-bw.de/en/location/pharma
  • Article - 06/05/2008

    Vetter clients can concentrate fully on their core business

    The Ravensburg-based company Vetter Pharma-Fertigung GmbH & Co. KG is one of the leaders in biopharmaceutical contract manufacturing. We spoke with Max Horn, who has been with the company since 1981 and was appointed Managing Director in 2002.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vetter-clients-can-concentrate-fully-on-their-core-business
  • Press release - 14/05/2008

    Vetter strengthens management team

    Vetters top management team is once again complete. As of June 1st 2008 Peter Soelkner will be heading a number of divisions at the Ravensburg-based company which specialises in the aseptic filling of prefilled injection systems. His new tasks will include Global Key Account Management Corporate Marketing Supply Chain Management and Project Management.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/vetter-strengthens-management-team
  • Press release - 13/08/2009 08265_de.jpg

    Sygnis published its financial results for the first quarter of 2009/2010

    SYGNIS Pharma AG published its financial results for the first quarter of the fiscal year 2009/2010, which ended on 30 June 2009.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-published-its-financial-results-for-the-first-quarter-of-2009-2010
  • Press release - 22/06/2011 SYGNIS Pharma AG Logo

    SYGNIS Pharma AG secures further financial resources with shareholder loan

    SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today executed a subordinated loan agreement for a total amount of EUR 6 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini), with an interest-rate at customary market conditions. As a result this loan, which is payable on demand, secures the financing of SYGNIS’ existing operations, according to the present plans, at…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sygnis-pharma-ag-secures-further-financial-resources-with-shareholder-loan
  • Press release - 13/10/2009

    Polyclone partners with Innovendia Consulting in Germany and Europe

    European biotech-platform and drug discovery companies will have easier access to Polyclone Bioservices assay design and validation services through its newly announced partnership with Innovendia Consulting from Owingen. EU and national government funded consortia will benefit from the more immediate availability of Polyclones unique combination of in vitro in silico assay design and validation capabilities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/polyclone-partners-with-innovendia-consulting-in-germany-and-europe

Page 1 / 8

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search